Key Highlights

  • For the third quarter, Waters Corporation (NYSE:WAT) expects Revenue of USD 1.745 billion to USD 1.762 billion, versus USD 799.9 million a year ago. Most of that step-up comes from the acquired BD businesses.
  • Third quarter adjusted EPS is guided to USD 3.95 to USD 4.05, up from USD 3.40 a year ago. Consensus sits near USD 3.99, while the screener reads USD 4.00.
  • Organic growth reached 9 percent in constant currency in the second quarter. Pharma and academic and government each rose 11 percent, and GLP-1 testing grew more than 40 percent.
  • The shares have gained about 18 percent over three months, and the report is due before the open on November 3, 2026.

What Waters Is Expected To Report

Waters Corporation (NYSE:WAT) reports before the open on Tuesday, November 3, 2026. Guidance for revenue of USD 1.745 billion to USD 1.762 billion is about 2.2 times the USD 799.9 million of a year earlier, simple arithmetic, mostly from acquired businesses. Adjusted EPS guidance of USD 3.95 to USD 4.05 is up about 17 percent at consensus. Full-year organic growth is guided to 7 percent to 9 percent, with an adjusted Operating Margin of 28.2 percent, and a stronger dollar costs about USD 0.25 of annual EPS. Pharma Demand and GLP-1 testing, up more than 40 percent last quarter, are the demand drivers investors will track.

BD Integration, Savings And Demand

The second quarter showed the BD businesses growing 4 percent reported and 6 percent outside China, and management expects them to exit the year growing faster than 6 percent. Third quarter BD growth may look softer because a roughly USD 20 million trade inventory build in the prior year unwinds. Cost savings are about USD 75 million in 2026, with a USD 200 million run rate. Pricing realization was 90 basis points against a 150 basis point target. The FACSDiscover A7 cell analyzer launched commercially in mid-September 2026, and implied fourth quarter organic growth is roughly 4 percent.

Bull Case, Bear Case And Peer Read

In a bull case, Waters Corporation (NYSE:WAT) prints above USD 4.05, lifts the organic range and shares move through the USD 465.36 post-earnings high, about 2.6 percent above an estimated USD 453.70, simple arithmetic from a price about 2.5 percent below that high. In a bear case, BD softness or currency pulls EPS to the low end, and a stock far above its 200-day average near USD 368 gives back gains. Among peers, Thermo Fisher Scientific (NYSE:TMO) beat on October 21, 2026 with adjusted EPS of USD 6.68 against USD 6.40 and rose about 4.3 percent. Danaher (NYSE:DHR) rose about 4 percent the same day with bioprocessing orders up in the mid-teens.

Where Things Stand

Waters Corporation (NYSE:WAT) is indeed guided to roughly USD 1.75 billion of revenue against USD 799.9 million a year ago, and the headline gap is mostly the acquired BD businesses, not organic growth. The balance of evidence is supportive: peers beat and rallied on October 21, 2026, and Waters raised guidance last quarter. The risks are a softer BD comparison, currency and a stock that has already climbed. The next catalyst is the November 3, 2026 release and the fourth quarter organic outlook. This is a preview, not a forecast of results.